• News
  • SAN DIEGO
  • Health

Illumina names Epstein to board

Illumina Inc. (Nasdaq: ILMN) Thursday announced that Dr. Robert S. Epstein, M.D., has joined the company’s board of directors.

He is an epidemiologist who worked in public health and academia before joining the private sector.

From 2010 to 2012, Epstein was chief R&D officer and president of Medco-UBC, a 2,400-person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes and comparative effectiveness research on behalf of the biopharmaceutical, medical device and diagnostics industries.

Prior to this role, Epstein was Medco’s chief medical officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting.

In addition, he is the former president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life.

Epstein has published more than 75 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals, including the "New England Journal of Medicine" and "JAMA."

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!